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Abstract
IMPORTANCE The benefits of responsible sharing of individual-participant data (IPD) from clinical
studies are well recognized, but stakeholders often disagree on how to align those benefits with
privacy risks, costs, and incentives for clinical trialists and sponsors. The International Committee of
Medical Journal Editors (ICMJE) required a data sharing statement (DSS) from submissions reporting
clinical trials effective July 1, 2018. The required DSSs provide a window into current data sharing
rates, practices, and norms among trialists and sponsors.
OBJECTIVE To evaluate the implementation of the ICMJE DSS requirement in 3 leading medical
journals: JAMA, Lancet, and New England Journal of Medicine (NEJM).
DESIGN, SETTING, AND PARTICIPANTS This is a cross-sectional study of clinical trial reports
published as articles in JAMA, Lancet, and NEJM between July 1, 2018, and April 4, 2020. Articles not
eligible for DSS, including observational studies and letters or correspondence, were excluded. A
MEDLINE/PubMed search identified 487 eligible clinical trials in JAMA (112 trials), Lancet (147 trials),
and NEJM (228 trials). Two reviewers evaluated each of the 487 articles independently.
EXPOSURE Publication of clinical trial reports in an ICMJE medical journal requiring a DSS.
MAIN OUTCOMES AND MEASURES The primary outcomes of the study were declared data
availability and actual data availability in repositories. Other captured outcomes were data type,
access, and conditions and reasons for data availability or unavailability. Associations with funding
sources were examined.
RESULTS A total of 334 of 487 articles (68.6%; 95% CI, 64%-73%) declared data sharing, with
nonindustry NIH-funded trials exhibiting the highest rates of declared data sharing (89%; 95% CI,
80%-98%) and industry-funded trials the lowest (61%; 95% CI, 54%-68%). However, only 2 IPD sets
(0.6%; 95% CI, 0.0%-1.5%) were actually deidentified and publicly available as of April 10, 2020. The
remaining were supposedly accessible via request to authors (143 of 334 articles [42.8%]),
repository (89 of 334 articles [26.6%]), and company (78 of 334 articles [23.4%]). Among the 89
articles declaring that IPD would be stored in repositories, only 17 (19.1%) deposited data, mostly
because of embargo and regulatory approval. Embargo was set in 47.3% of data-sharing articles (158
of 334), and in half of them the period exceeded 1 year or was unspecified.
CONCLUSIONS AND RELEVANCE Most trials published in JAMA, Lancet, and NEJM after the
implementation of the ICMJE policy declared their intent to make clinical data available. However, a
wide gap between declared and actual data sharing exists. To improve transparency and data reuse,
journals should promote the use of unique pointers to data set location and standardized choices for
embargo periods and access requirements.
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Introduction
Responsible sharing of individual-participant data (IPD) from clinical studies has gained increasing
traction and has been advocated for many years by many scientists and scientific leadership
organizations.1 However, promoting data sharing from clinical trials has not been straightforward,
and there has been much debate surrounding privacy risks and the optimal incentives for clinical
trialists and sponsors.2-6 Recently, the International Committee of Medical Journal Editors (ICMJE)
implemented a clinical trial data sharing policy. The policy does not mandate7,8 data sharing but
requires a data sharing statement (DSS) from submissions reporting clinical trials effective July
1, 2018.9-11
Prior work has identified a range of potential risks preventing trialists from sharing IPD.3,12,13
These risks include protection of patient privacy and confidentiality,4,13 inappropriate data reuse and
replication,12 and researchers’ and sponsors’ potential losses of secondary publications and product
advantage, respectively, because of the use of the shared data by competitors.3,5,14 Repositories for
clinical data from industry-funded15-17 and publicly funded18 trials have provided a safeguarded
mechanism for responsible IPD sharing, thereby substantially minimizing patient privacy and
confidentiality risks. However, perceived risks of inappropriate reuse and competition have been
difficult to mitigate, especially when the current reward system for researchers predominantly
incentivizes high-impact publications, often based on exclusive data, at the expense of transparency,
reproducibility, and data reuse.19-22
Disincentives for data sharing are known to have a disproportionate impact on clinical studies
because the process of conducting those studies is time, cost, and labor intensive.3 Yet the role of
prevalent disincentives and incentives (eg, data authorship23,24) for clinical trial data sharing have
only recently entered the public realm,3,23,25,26 in part accelerated by discussions surrounding the
ICMJE’s data sharing policy11,27 when many points of agreement and disagreement among
stakeholders were articulated.3,5,6,27,28
Many data repositories have been established to facilitate secure sharing of IPD from clinical
trials.15,17,18,29-32 Some industry sponsors, such as GlaxoSmithKline and Johnson & Johnson, have
initiated their own data sharing repositories and partnerships with ClinicalStudyDataRequest.com
(CSDR)17 and the Yale University Open Data Access (YODA) Project,15 respectively. Foundations and
research charities, such as Wellcome Trust, Cancer Research UK, the Bill and Melinda Gates
Foundation, and the UK Medical Research Council, have also implemented clinical trial data sharing
policies and are now members of the CSDR platform.5,33 Information on CSDR, the YODA Project, and
other clinical trial data repositories can be found in the eTable in the Supplement.
Following the 2003 Data Sharing Policy34 that encouraged data plan and sharing of grants
exceeding $500 000, the National Institutes of Health (NIH) have implemented disease-specific
data repositories, including the Biologic Specimen and Data Repository Information Coordinating
Center,18 which is supported by the National Heart, Lung, and Blood Institute (NHLBI), and the
NCTN/NCORP Data Archive for data sets from clinical trials of the National Clinical Trials Network
(NCTN) and the NCI Community Oncology Research Program (NCORP), which is supported by the
National Cancer Institute. Recently, the NIH announced new Policy for Data Management and
Sharing35 with direct implications for clinical trial data sharing.21
Prior research has identified differences in clinical trial data sharing across funders and
sponsors.30,36,37 Historically, sharing of clinical trial data has been more prevailing among industry
funders and sponsors associated with data repositories. For example, for a subset of drugs and
industry sponsors (ie, Roche, Lilly, Boehringer Ingelheim, and GlaxoSmithKline), Boutron et al30
found that 53% (512 of 966 randomized clinical trials) of clinical trials registered on ClinicalTrials.gov
were listed on CSDR, and for 40% (385 of 966 randomized clinical trials) of the trials all documents
were available, including raw data sets. Academic research has been less engaged with clinical trial
data sharing. For instance, a prominent NIH repository such as the NHLBI Data Repository contained
only 100 studies as of May 31, 2016.18 However, a study37 of trialists’ intentions to share IPD from
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clinical trials registered on ClinicalTrials.gov between January 2016 and August 2017 found that
NIH-funded trials were more likely to indicate data sharing intentions than industry-funded trials.
The ICMJE policy requires investigators to state whether they will share data (or not) while
simultaneously providing an opportunity for them to place multiple restrictions and conditions
regarding data access. Specifically, the DSS provides an opportunity for authors and sponsors to
specify periods of data exclusivity or embargo. In addition, authors can specify in the DSS how the
data will be made available, reasons for data availability or unavailability, and related preferences (for
examples of DSSs, see eAppendix 1 in the Supplement). Thus, the DSSs, required by the ICMJE’s
policy, provide a window into data sharing norms, practices, and perceived risks among trialists and
sponsors. We set out to evaluate how the ICMJE’s data sharing policy has been implemented in 3
leading medical journals that are also member journals of ICMJE: JAMA,9 Lancet,10 and New England
Journal of Medicine (NEJM).11
Methods
Because this study used publicly available data and did not involve human participants, institutional
review board approval and informed consent were not sought, in accordance with 45 CFR §46. The
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline38
was used as a guideline for this observational study. In particular, the STROBE checklist for
cross-sectional studies was used to ensure accurate reporting.
The inclusion criteria in this study were reports of clinical trials, published as articles in JAMA,
Lancet, and NEJM between July 1, 2018, and April 4, 2020, and containing a DSS. Excluded from the
study were publications that contained no DSS because the article was submitted prior to July 1,
2018; was an observational or other type of study that is different from clinical trial and is, therefore,
not required to contain a DSS under the ICMJE policy; or was a letter, correspondence, or other type
of publication that lacks a DSS.
A MEDLINE/PubMed search of clinical trials published in the 3 journals between July 1, 2018,
and April 4, 2020, identified 629 potentially eligible articles; 486 of them included a DSS, whereas
the others were either submitted before July 2018, were not a clinical trial, or were letters. One article
published in 2020 met all other inclusion criteria but contained no DSS and was included in the study
sample as not sharing data because articles published in 2020 were likely submitted after July 1,
2018, and were, therefore, required to contain a DSS. We conducted a cross-sectional observational
study for all 487 articles in JAMA (112 articles), Lancet (147 articles), and NEJM (228 articles) (eFigure
in the Supplement). Two reviewers evaluated each article independently. Discrepancies were
resolved unanimously or by a third reviewer.
Data were classified as being available when authors answered yes (JAMA and NEJM) or gave an
unstructured positive response (Lancet) to the data availability question. Information about data
type, access, conditions, and reasons for data availability or unavailability were taken from the DSS
(eAppendix 2 in the Supplement). We also compared declared with actual data availability in
repositories by examining whether information about data and data themselves are available in the
respective repository. For more details on the MEDLINE/PubMed search strategy, inclusion and
exclusion criteria for the study, definition of variables, and data extraction, see eAppendix 3 in the
Supplement.
Drawing on prior research reporting differences in intention to share clinical trial data between
industry-funded and nonindustry (including NIH)–funded clinical trials,37 we classified funding
sources as industry, nonindustry NIH, nonindustry non-NIH, and mixed. Industry refers to research
funding from companies. Nonindustry NIH refers to research funding from the US NIH. Nonindustry
non-NIH refers to research funding from foundations, trusts, associations, national institutes outside
the US, and so forth. Mixed refers to any combination of the other research-funding categories.
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Statistical Analysis
We conducted a descriptive analysis of variables associated with data sharing by type of funding and
publication journal. For the primary outcome variables, declared and actual data sharing, we report
the 95% CIs determined by bootstrapping (100 000 iterations). The χ2 test was used for comparing
differences in prevalence of declared data sharing between types of funding. The 2-tailed Fisher
exact test was used for comparing differences in prevalence of data availability in repositories
between types of funding. P < .05 was considered significant. To perform data analysis and to
generate summary statistics and graphs, we used the Python programming language version 3.8.3
(Python Software Foundation), a Jupyter Notebook,39 and the following libraries: SciPy,40 Pandas,41
NumPy,42 Matplotlib,43 Scikits-Bootstrap,44 and Seaborn.45 For the statistical tests, we used the
Python package Statsmodels and R statistical software version 4.0.2 (R Project for Statistical
Computing).
Results
Overall, 334 of 487 articles (68.6%; 95% CI, 64%-73%) declared data sharing (Table 1). The
prevalence of declared data sharing varied by funder type for all 487 articles (χ 23 = 15.93; P = .001).
Nonindustry NIH-funded trials had the highest rates of declared data sharing (89%; 95% CI,
80%-98%) and industry-funded trials had the lowest rates (61%; 95% CI, 54%-68%) (Figure 1A).
The ranking of funders regarding declared data sharing is largely consistent across the 3 journals—
NIH, nonindustry non-NIH, mixed, and industry—although the 95% CIs overlap (Figure 1B). No
substantial changes in the prevalence of declared data sharing were observed over the span of the
first 7 quarters of policy implementation (Figure 1C).
The presence of multiple articles from the same clinical trials would violate the assumption of
independence and could also introduce social dependencies,46 such as clustering by authors, funder,
or institution. To address this issue, we identified 12 clusters of multiple publications for the same
trial. Each cluster contained 2 or (in 1 instance) 3 articles that had the same declared data sharing and
funding source and were associated with common authors and institutions. We treated each cluster
as a single article observation (474 articles) and recomputed our results about declared data sharing
by funding as a way of assessing the impact of clustering on our results. Results were qualitatively
similar: 326 of 474 articles declared data sharing (68.8%; 95% CI, 64%-73%), and differences in
declared data sharing by funding sources were similar to the ones in the entire data set: NIH (88.4%;
95% CI, 79%-98%), nonindustry non-NIH (73.5%; 95% CI, 67%-80%), mixed (65.4%; 95% CI,
55%-76%), and industry (61.2%; 95% CI, 54%-68%). Owing to the small effect of clustering of
articles from the same trial, the subsequent analysis uses the entire data set of 487 articles.
Industry sponsors had the lowest rate of declared data sharing in our sample. To examine
further, we sampled industry sponsors that are members of the largest industry-initiated registry,
CSDR, as of November 8, 2020, and identified the following industry sponsors with 1 or more studies
in our sample: GlaxoSmithKline (10 studies), Novartis (10 studies), Bayer (6 studies), ViiV Healthcare
(3 studies), ONO Pharmaceutical (2 studies), Sanofi (2 studies), Eisai (2 studies), Astellas (1 study),
and Chugai (1 study). All of those industry sponsors are listed as current members of CSDR; industry
sponsors that declared in their DSS that they would deposit data in CSDR but were not listed as
members of the registry were excluded from this analysis. The rate of declared data sharing for all
industry members of CSDR (56.8%; 95% CI, 38%-70%) was similar to the rate we established for all
industry-funded trials (61.3%; 95% CI, 54%-68%). We could, therefore, exclude the possibility that
the lowest rate of declared data sharing of industry funders is due to differences between companies
that are members of data repositories and companies that are not members of data repositories.
Regarding type of shared data, 76.3% (255 of 334) of the articles proposed to provide
deidentified IPD, 22.8% (76 of 334) would provide unspecified or partial data, and 0.9% (3 of 334)
would provide aggregate data only. Only 2 of 334 IPD sets (0.6%; 95% CI, 0.0%-1.5%) were actually
deidentified and publicly available (on journal website) as of April 10, 2020 (both data sets were
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associated with the same clinical trial). The remaining were supposedly accessible via request to
authors (143 of 334 articles [42.8%]), repository (89 of 334 articles [26.6%]), and company (78 of
334 articles [23.4%] overall; 72 of 114 articles [63.2%] among industry-funded trials).
Conditions for access to data included embargo (158 of 334 articles [47.3%]), product approval
(37 of 334 articles [11.1%]), and collaboration (9 of 334 articles [2.7%]). Among the 158 articles
specifying embargo, approximately one-half required 1 year or less of data exclusivity. In the other
half of embargo cases, the embargo period exceeded 1 year or was unspecified.













Declared data sharing, articles, No. (%)a
Yes 114 (61.3) 40 (88.9) 127 (73.4) 53 (63.9) 334 (68.6)
No 72 (38.7) 5 (11.1) 46 (26.6) 30 (36.1) 153 (31.4)
Journal, articles, No. (%)
JAMA 21 (11.3) 18 (40.0) 50 (28.9) 23 (27.7) 112 (23.0)
Lancet 57 (30.6) 7 (15.6) 64 (37.0) 19 (22.9) 147 (30.2)
New England Journal of Medicine 108 (58.1) 20 (44.4) 59 (34.1) 41 (49.4) 228 (46.8)
Type of declared available datab
Deidentified individual-participant data 83/114 (72.8) 33/40 (82.5) 95/127 (74.8) 44/53 (83.0) 255/334 (76.3)
Aggregate data only 2/114 (1.8) 0/40 (0.0) 1/127 (0.8) 0/53 (0.0) 3/334 (0.9)
Unspecified or partial datac 29/114 (25.4) 7/40 (17.5) 31/127 (24.4) 9/53 (17.0) 76/334 (22.8)
Access to datad
Request to authors 9/114 (7.9) 15/40 (37.5) 96/127 (75.6) 23/53 (43.4) 143/334 (42.8)
Request to committee, group, or unit 15/114 (13.2) 3/40 (7.5) 36/127 (28.3) 13/53 (24.5) 67/334 (20.1)
Request to repository or archive 46/114 (40.4) 22/40 (55.0) 5/127 (3.9) 16/53 (30.2) 89/334 (26.6)
Request to company 72/114 (63.2) 0/40 (0.0) 0/127 (0.0) 6/53 (11.3) 78/334 (23.4)
Access unspecified 5/114 (4.4) 2/40 (5.0) 5/127 (3.9) 3/53 (5.7) 15/334 (4.5)
Data are available to others 0/114 (0.0) 0/40 (0.0) 2/127 (1.6) 0/53 (0.0) 2/334 (0.6)
Conditional data accessd
Data embargo 49/114 (43.0) 22/40 (55.0) 57/127 (44.9) 30/53 (56.6) 158/334 (47.3)
Up to 1 ye 20/114 (17.5) 13/40 (32.5) 30/127 (23.6) 18/53 (34.0) 81/334 (24.3)
>1 y to 2 y 13/114 (11.4) 7/40 (17.5) 13/127 (10.2) 6/53 (11.3) 39/334 (11.7)
>2 y 4/114 (3.5) 2/40 (5.0) 4/127 (3.1) 5/53 (9.4) 15/334 (4.5)
Product approval 36/114 (31.6) 0/40 (0.0) 0/127 (0.0) 1/53 (1.9) 37/334 (11.1)
Collaboration 0/114 (0.0) 2/40 (5.0) 6/127(4.7) 1/53 (1.9) 9/334 (2.7)
Reasons for why data not availabled
No reason given 40/72 (55.6) 2/5 (40.0) 26/46 (56.5) 15/30 (50.0) 83/153 (54.2)
Data privacy 3/72 (4.2) 1/5 (20.0) 9/46 (19.6) 2/30 (6.7) 15/153 (9.8)
Time and cost 0/72 (0.0) 0/5 (0.0) 2/46 (4.3) 0/30 (0.0) 2/153 (1.3)
Ongoing trial or research 2/72 (2.8) 0/5 (0.0) 2/46 (4.3) 9/30 (30.0) 13/153 (8.5)
Regulatory approval 3/72 (4.2) 0/5 (0.0) 1/46 (2.2) 0/30 (0.0) 4/153 (2.6)
Proprietary data 7/72 (9.7) 0/5 (0.0) 4/46 (8.7) 3/30 (10.0) 14/153 (9.2)
Shared among coinvestigators only 2/72 (2.8) 0/5 (0.0) 0/46 (0.0) 0/30 (0.0) 2/153 (1.3)
Data may be available for collaboration 6/72 (8.3) 0/5 (0.0) 0/46 (0.0) 1/30 (3.3) 7/153 (4.6)
Data may be available upon request 19/72 (26.4) 2/5 (40.0) 6/46 (13.0) 7/30 (23.3) 34/153 (22.2)
a The denominators represent the total for the respective column, unless otherwise
indicated.
b Detailed definitions of variables are provided in eAppendix 2 in the Supplement.
c Among the articles not specifying the type of data, 13 intended to store data in clinical
trial data repositories, presumably individual-participant data, and 1 made available (via
collaboration) individual-participant data in a designated repository.
d Categories are not mutually exclusive.
e Time periods are not specified in all articles proposing data embargo.
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Data repositories have a central role in improving sharing, security, discoverability, and reuse of
research data,47,48 particularly IPD from clinical trials.29,36,49 Among the 89 articles proposing to
make IPD available through repositories, many planned to store data in general-purpose repositories,
including the CSDR (31 articles), the YODA Project (7 articles), and Vivli (7 articles). Another 30
articles planned to store IPD in NIH-supported, domain-specific data repositories, such as the NCTN/
NCORP Data Archive (10 articles), the NHLBI Biologic Specimen and Data Repository Information
Coordinating Center (9 articles), and the National Institute of Child Health and Human Development
Data and Specimen Hub (5 articles) (Figure 2).
We compared declared with actual data availability in repositories (Table 2). Among 89 articles,
information about the data was infrequently available in the repository (20 of 89 articles [22.5%])
and the data themselves were even more infrequently available there (17 of 89 articles [19%.1])
(Figure 3). Although data of NIH-funded trials (7 of 22 articles [31.8%]) were somewhat more likely
to be available in repositories than data from industry-funded trials (7 of 46 articles [15.2%]),
nonindustry non-NIH trials (0 of 5 articles), and trials with mixed funding (3 of 16 articles [18.8%]),
data availability in repositories was not associated with type of funding (P = .32, Fisher exact test).
Most trials provided neither information nor data in the respective repositories, mostly because of
embargo and pending regulatory approval. Specifically, among the 72 articles that declared their
intent but did not store data on repository, 37 (51%) made data access conditional on embargo or
product approval.
Figure 1. Declared Clinical Trial Data Sharing in 3 Leading Medical Journals













































































Publication data (in quarters)
Changes in prevalence  C
Funder type
Journal
Graphs show prevalence of data sharing by funder (A)
and journal (B) and changes in prevalence between
2018 and 2020 (C). Error bars denote 95% CIs. NEJM
indicates New England Journal of Medicine; NIH,
National Institutes of Health.
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Among reasons for data withholding, articles referred to data privacy (15 of 153 articles [9.8%]),
proprietary data (14 of 153 articles [9.2%]), ongoing research (13 of 153 articles [8.5%]), and pending
regulatory approval (4 of 153 articles [2.6%]). Most articles withholding data (83 of 153 articles
[54.2%]) provided no reason. One article, which had no intent to make data available to others, was
retracted.
Discussion
Most trials published in JAMA, Lancet, and NEJM after the endorsement of the ICMJE policy declared
their intent to make clinical data available. Non–industry-funded trials communicated greater intent
to share data than industry-funded trials, which exhibited low declared data sharing rates even
among industry funders that are members of the largest data sharing repository, the CSDR. This
result is consistent with prior research on intention to share data at the ClinicalTrials.gov37 but
departs from a trend among industry sponsors to establish mechanisms and repositories for sharing
of clinical trial data.15,17,30,31,50
The commitment to data sharing substantially decreases when we consider indicators of actual
vs declared data sharing: of 334 articles declaring that they would share data, only 2 IPD sets (0.6%;
95% CI, 0.0%-1.5%) were actually deidentified and publicly available on the journal website. Among
the 89 articles declaring that they would store IPD in repositories, data from only 17 articles were
found in the respective repository (Figure 3).
Although it is encouraging that data sharing appears widespread as a research norm51 among
trialists and that repositories for secure data sharing are often considered in DSSs, the low rate of
actual data availability we identified is concerning. Some data sets that are currently unavailable may
simply require additional time to be released, particularly those that are associated with embargo
periods, but for many unavailable data sets, actionable information about availability is lacking. This
points to the need for detailed requirements that encourage authors to engage with tangible and
Figure 2. Ranking of Data Repositories by the Number of Articles Intending
to Share Individual-Participant Data (IPD) in the Respective Repository
0
Articles intending to share IPD in repositories, No.
355 1510 2520 30
ClinicalStudyDateRequest.com
Other
The Jaeb Center for Health Research
NIDDK Central Repository
Bern Open Repository and Information System
NINDS Archived Clinical Research Datasets
NICHD Data and Specimen Hub
Vivli Center for Global Clinical Research Data
The Yale Open Data Access Project
BioLINCC NHLBI Biospecimens and Data
NCTN/NCORP Data Archive
BioLINCC indicates Biologic Specimen and Data
Repository Information Coordinating Center; NCORP,
National Cancer Institute Community Oncology
Research Program; NCTN, National Clinical Trials
Network; NHLBI, National Heart, Lung, and Blood
Institute; NICHD, National Institute of Child Health and
Human Development; NIDDK, National Institute of
Diabetes and Digestive and Kidney Diseases; and
NINDS, National Institute of Neurological Disorders
and Stroke.














is logged in repository
9 (19.6) 7 (31.8) 1 (20.0) 3 (18.8) 20 (22.5)
Data are available on
repository to request
7 (15.2) 7 (31.8) 0 (0.0) 3 (18.8) 17 (19.1)
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verifiable steps toward data sharing at or before publication, including logging information about the
data sets in a data repository and having time-stamped information about their planned future
release. Stakeholders, including journals, funders, and research institutions, should specifically focus
on policies that could narrow the wide gap we identified between declared data sharing and actual
availability of clinical trial IPD.
Consistent with prior research of clinical trial data registries30,37 and DSSs,7 the language of
DSSs was often ambivalent. Offering of aggregate data, collaboration demands, lengthy or
unspecified embargo periods, and the use of legacy methods for access such as author or company
request communicate only lukewarm commitment. Repositories can be instrumental for sharing, but
real practices may diverge from intent.
The current ICMJE requirement for DSSs is restricted to clinical studies. The policy restriction
may be unwarranted given the high-profile observational studies recently retracted in Lancet52 and
NEJM53 because of concerns regarding data veracity and availability, pointing to potential benefits of
extending data sharing requirements to observational studies.54-56
Figure 3. Indicators of Declared and Actual Clinical Trial Individual-Participant Data (IPD) Availability as of April 10, 2020
AvailableUnavailable
Articles declaring to make clinical trial data available
Articles declaring to make IPD available
Articles declaring to make IPD available on repository
Articles providing deidentified IPD on repository
Articles providing IPD publicly available for others to use
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Limitations
Our study has limitations that should be acknowledged. First, only 3 journals were considered.
Moreover, we could readily investigate declared vs actual data sharing practices only for repositories.
Furthermore, only 2 IPD sets were deidentified and available on journal websites, so we could not
meaningfully examine the usability of shared data or reproducibility8 of the clinical trial studies. As
more IPD sets become available, it would be interesting to assess whether they are easy to use, and
how complete is the information being provided. More broadly, a repeated evaluation of data sharing
intentions and practices could be valuable, particularly in the context of the ongoing clinical trial
research response to the coronavirus disease 2019 pandemic that may have changed some norms
and practices of clinical research.56-59 In addition, we determined that repeated articles from the
same clinical trial have very small effect on our estimates but did not examine clustering by authors
and institutions that could occur beyond the level of single trials.
Conclusions
To promote transparency and data reuse, journals and funders should work toward incentivizing data
sharing via funding mechanisms21 and data authorship,23 and simultaneously discourage ambivalent
wording in DSSs and possibly mandate data sharing. They can promote the use of unique pointers
to data set location in repositories and to data request forms. Standardized choices for embargo
periods, access requirements, and conditions for data use as part of the data sharing process could
also reduce unnecessary data withholding and turn declarative data sharing into actual transparency
in clinical trial data.
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